Supplemental New Drug Application (sNDA) for icosapent capsules (VascepaT) for hypertriglyceridaemia and mixed dyslipidaemia
Source: BioSpace
Area: News
Amarin Corporation has submitted a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) seeking approval for icosapent ethyl capsules (VascepaT) for use as an adjunct to diet in the treatment of adult patients with hypertriglyceridaemia (triglyceride (TG) =200 mg/dL and <500 mg/dL) with mixed dyslipidaemia.
The FDA has approved the product (an ultrapure capsule containing 96% eicosapentaenoic acid), as an adjunct to diet to reduce TG levels in adult patients with severe hypertriglyceridaemia (TG ?500mg/dL/ 5.69 mmol/L).
[Editors note: Icosapent ethyl capsules are not licensed within the EU.]
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Food and Drug Administration (FDA) | Heart | New Drug Applications | Nutrition